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Abstract
Background: Huntington’s disease (HD), is a neurodegenerative disorder that is associated with 
cognitive, behavioral, and motor impairments that diminish health related quality of life 
(HRQOL). The HD-PRO-TRIAD™ is a quality of life measure that assesses health concerns 
specific to individuals with HD. Preliminary psychometric characterization was limited to a 
convenience sample of HD participants who completed measures at home so clinician-ratings 
were unavailable.
Objectives: The current study evaluates the reliability and validity of the HD-PRO-TRIAD™ in 
a well-characterized sample of individuals with HD.
Methods: Four-hundred and eighty-two individuals with HD (n = 192 prodromal, n = 193 early, 
and n = 97 late) completed the HD-PRO-TRIAD™ questionnaire. Clinician-rated assessments 
from the Unified Huntington Disease Rating Scales, the short Problem Behaviors Assessment, and 
three generic measures of HRQOL (WHODAS 2.0, RAND-12, and EQ-5D) were also examined.
Results: Internal reliability for all domains and the total HD-PRO-TRIAD™ was excellent (all 
Cronbach’s α > 0.93). Convergent and discriminant validity were supported by significant 
associations between the HD-PRO-TRIAD™ domains, and other patient reported outcome 
measures as well as clinician-rated measures. Known groups validity was supported as the HD-
PRO-TRIAD™ differentiated between stages of the disease. Floor and ceiling effects were 
generally within acceptable limits. There were small effect sizes for 12-month change over time 
and moderate effect sizes for 24-month change over time.
Conclusions: Findings support excellent internal reliability, convergent and discriminant 
validity, known groups validity, and responsiveness to change over time. The current study 
supports the clinical efficacy of the HD-PRO-TRIAD™. Future research is needed to assess the 
test-retest reliability of this measure.
Keywords
HD-PRO-TRIAD™; health-related quality of life; Huntington’s disease; patient reported outcome 
(PRO); psychometric; reliability; validity
INTRODUCTION
Huntington’s disease (HD) is a neurodegenerative disorder that is estimated to affect 
between 3 and 10 of every 100,000 individuals worldwide [1, 2]. HD is an autosomal-
dominant disorder that is caused by the presence of 36 or more CAG trinucleotide repeats in 
the gene coding for the huntingtin protein, which is located on the short arm of chromosome 
4 [3]. HD is diagnosed on average around age 40 and symptoms progressively worsen until 
death (course is ~20 years) [4]. The symptoms of HD commonly occur as a ‘triad’ of motor, 
cognitive, and behavioral deficits [5]. Behavioral and psychiatric symptoms often appear 
prior to the onset of motor symptoms [6, 7]. Behavioral symptoms include depression, 
anxiety, apathy and irritability [8]. Common motor complaints include uncontrollable 
movements such as chorea or dystonia, loss of balance, and incoordination [9]. Cognitive 
symptoms can include a decline in executive function, memory problems, and difficulty 
concentrating [7, 10–12].
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Not surprisingly, HD symptoms can have a detrimental effect on health related quality of life 
(HRQOL) [13], or the effect of a disease or disability on an individual’s physical, emotional, 
cognitive, and social well-being [14]. The first phase of HD-PROTRIAD™ development 
was to identify a conceptual framework upon which to base the new measure. Specifically, 
previous work highlights the utilization of the World Health Organization framework for 
HRQOL, in conjunction with a panel of HD experts (i.e., practitioners and nurses) and 
patients to identify the physical, emotional, and cognitive aspects of HRQOL that are most 
relevant to individuals with HD, as well as the most common core triad symptoms of HD 
[15]. Although a handful of measures have been developed to examine HRQOL specific to 
HD [16–21], psychometric properties to support their clinical utility is mixed (or not yet 
available). In some cases these measures are not designed to examine the full triad of 
symptoms in HD, or do not assess symptoms that are most important to HD patients (i.e., 
chorea, speech, swallowing) [15]. More generic measures have also been used in HD (in 
particular, the SF-36 and SF-12), but by design these measures do not evaluate HD-specific 
aspects of HRQOL (e.g., chorea), and data would suggest that these generic measures are 
typically not responsive to change over time [22, 23] or to treatment [24] which is a 
significant limitation given the progressive nature of the disease.
The purpose of the HD-PRO-TRIAD is to assess the HD symptom triad as they pertain to 
HRQOL. The HD-PRO-TRIAD™ is unique because it examines the full triad of HD 
symptoms. The HD-PROTRIAD™ was developed to mitigate the limitations of previous 
HD-specific and generic HRQOL measures by targeting the triad of symptom domains most 
relevant to HRQOL in HD [15, 25]. Additionally, the HD-PRO-TRIAD™ was designed to 
be easily administered and publicly available for clinicians and researchers to use via an 
online domain [25]. Initial development utilized phone interviews with HD patients and 
caregivers to create a domain framework that determined areas of HRQOL important to 
individuals with HD [15]. The measure was created using a pool of items from other 
established PRO measures including Neuro-QoL (Executive Function, General Concerns, 
and Emotional/Behavioral Dyscontrol) [26], TBI-QOL [27], HDQLIFE (Chorea) [18], and 
the Functional Assessment of Chronic Illness Therapy (FACIT) questionnaire [28]. The 
finalized items were then selected by a team of experts in HD, including practitioners and 
nurses. The HD-PROTRIAD™ is a 47-item questionnaire that evaluates the three domains 
that comprise the HD symptom triad, namely cognition, emotional and behavioral 
dyscontrol, and motor function. Each item is self-rated on a 5-point Likert scale [25]. Final 
scores for each symptom domain range from 1 to 5, with lower scores representing higher 
functioning and high scores representing worse functioning (details for how to convert raw 
scores to final scores for each domain are detailed elsewhere [25]). The total score is 
calculated by summing the final scores from each of the domains. Total scores range from 3 
to 15 with higher scores associated with worse outcomes [25].
The HD-PRO-TRIAD™ was previously validated in a cross-sectional study consisting of 
132 patients with HD and 40 caregivers, and was found to have good internal consistency 
(Cronbach’s α >0.95) [25]. Additionally, the HD-PRO-TRIAD™ had strong convergent and 
discriminant validity among the three domains, as each domain was strongly correlated with 
comparator measures (r > 0.50) and were not as strongly correlated with non-comparator 
measures [25]. However, the previous study noted that the survey was completed by 
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participants at home, and therefore self-reported stage of disease, functional ability, and 
independence could not be verified by a clinician. Researchers were also unable to verify 
whether the individual with HD had completed the survey as instructed without input from 
their caregiver. The current study aims to replicate the reliability and validity findings for the 
HD-PROTRIAD™ and to provide additional information about floor and ceiling effects, 
measurement error, known groups validity using clinician-rated disease status, and 
responsiveness to change over time.
MATERIALS AND METHODS
Data for the validation of the HD-PRO-TRIAD™ were analyzed retrospectively from a 
longitudinal study that examines HRQOL at baseline, 12- and 24-months [16]; a detailed 
description of the broader study protocol is reported elsewhere [16]. Recruitment for this 
study also took place in collaboration with the PREDICT-HD study, a global cohort study 
with the purpose of assessing early symptoms of HD in prodromal individuals; ~36% (n = 
173) of participants were recruited in conjunction with the PREDICT-HD study [29]. In 
addition to completing several core assessments as a part of their PREDICT-HD study visit, 
these individuals also agreed to complete additional self-report measures that were specific 
to this study protocol. The remaining 64% (N = 309) of participants were recruited through 
other recruitment sources [16]. All data were collected in accordance with and approval of 
the local institutional review boards. To be eligible for the study, participants were required 
to have a positive gene test and/or a clinical diagnosis (made by a neurologist, physician, or 
other medical professional) of HD and be ≥18 years of age. Participants were alsorequired to 
be capable of providing informed consent; cognitive status was assessed using a standard 
assessment [30].
Participant visits
Participants were recruited through eight established HD clinics (Los Angeles, CA; Iowa 
City, IA; Indianapolis, IN; Baltimore, MD; Ann Arbor, MI; Golden Valley, MN; St. Louis, 
MO; Piscataway, NJ), the National Research Roster for Huntington’s Disease, online 
medical record data capture systems [31], and through articles/advertisements in HD-
specific newsletters and websites. Recruitment also included HD support groups and HD 
specialized nursing home units throughout the United States. Participants completed an in-
person assessment, which was followed by a computer based survey regarding HRQOL. For 
baseline visits, continue their participation, were given the option of being interviewed via 
telephone given that previous work does not find differences regarding mode of 
administration [32, 33]. Each study visit lasted approximately two hours (ninety minutes for 
phone visits, as motor and cognitive assessments that required in-person contact were not 
administered).
Measures
Demographic variables—Participants were asked to self-report demographic 
information (age, gender, marital status, race, and ethnicity) through Assessment CenterSM, 
an online data collection platform [34].
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Medical record confirmation—After obtaining informed consent from the participants, 
researchers retrieved participant medical records to confirm their HD diagnosis and to 
collect data regarding the CAG repeats from the results of any previous genetic testing in the 
record.
HD-PRO-TRIAD™ items [25]—All self-report measures were completed during the 
study visit on Assessment CenterSM within two weeks of the clinician interview. Participants 
were asked to recall their quality of life using questions from the previously developed and 
validated HDPRO-TRIAD™ questionnaire [25] at the baseline, 12- and 24-month visits. 
The HD-PRO-TRIAD™ consists of three domains: Cognition, Emotional and Behavioral 
Dyscontrol, and Motor Functioning. The Cognition domain asks questions regarding self-
reported memorization, concentration, and ability to learn new tasks. These items were 
drawn from Neuro-QoL measures (Executive Function, General Concerns) and TBI-QOL 
Cognition items [35–37]. The Emotional and Behavioral Dyscontrol domain asks 
participants to answer questions about impulsivity, irritability, and violent or aggressive 
behavior. These items were taken from the Neuro-QoL measure of Emotional and 
Behavioral Dyscontrol [37]. The Motor domain asks for a self-report assessment of a 
participant’s movements, and how frequently these movements impact activities of daily 
living. These items were taken from the newly developed HDQLIFE Chorea item bank and 
from the Functional Assessment of Chronic Illness Therapy (FACIT) questionnaire [18, 28]. 
Some of the questions from the original HD-PRO-TRIAD™ [25] were omitted from the 
current study because these items were drawn from measures that were not evaluated for the 
purpose of relieving participant burden (i.e., Functional Assessment of Chronic Illness 
Therapy or FACIT [28] and TBI-QoL [27]). The HD-PROTRIAD™ scoring guide [25] 
allows for calculation despite missing values assuming each participant answers at least 8 of 
14 cognitive items, 8 of 14 emotional and behavioral dyscontrol items, and 10 of 19 items 
from the Motor domain. In total, 9 questions were administered from the Cognitive domain, 
13 questions from the Emotional and Behavioral Dyscontrol domain, and 13 questions from 
the Motor Functioning domain (see Appendix A for the complete list of items that were 
administered) thus exceeding the minimum criteria required for scoring. Participants who 
did not answer the minimum number of items in each domain were excluded from analyses 
(n = 54 were excluded from the baseline assessments, n = 32 from 12- and n = 177 from 24-
months).
Quality of life in neurological disorders (Neuro-QoL) item banks [38, 39]—
Neuro-QoL [38, 39], from which some HD-PROTRIAD™ Emotional and Behavioral 
Dyscontrol and some Cognitive items were drawn, is a patient reported outcome 
measurement system designed to evaluate HRQOL in individuals with neurological 
conditions. Convergent and discriminant validity were examined using the Neuro-QoL 
measures of Upper Extremity Function and Lower Extremity Function from the baseline 
visit. Items were completed on a 5-point Likert scale. Neuro-QoL measures are scored using 
a T-score metric with a mean of 50 and a standard deviation (SD) of 10 [40]. Higher scores 
are representative of better functioning.
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Patient Reported Outcomes Measurement Information System (PROMIS) item 
banks [41, 42]—PROMIS® [41, 42] is a measurement system designed to evaluate 
HRQOL across a diverse range of health issues. Convergent and discriminant validity was 
examined by using PROMIS Depression, Anxiety, and Anger baseline data. These measures 
were self-reported on a 5-point Likert Scale that ranged from “Not at All” to “Very Much”. 
All measures are scored using a T-score metric with a mean of 50 and a standard deviation 
(SD) of 10 [41]. Higher scores indicate worse functioning.
EQ-5D [43]—The EQ5D [43] is a generic self-report measure of HRQOL that generates 
two different scores: the Index Scale score and a Health Scale score. This measure was 
administered at all three study visits. The EQ-5D Index Scale includes 5 items that assesse 
mobility, self-care, ability to perform usual activities, pain/discomfort, and anxiety/
depression. Each item is rated from 0 (no problems) to 5 (severe problems or impairments), 
and then summed to create a total score. The EQ5D Health Scale includes a single item that 
assesses overall health status; this scale is rated from 0 to 100 with higher scores indicating 
better overall health. The baseline EQ5D Index Score was used to examine convergent and 
discriminant validity. Baseline scores on the EQ-5D Health Scale were subtracted from both 
12-month and 24-month scores to determine change scores to examine responsiveness to 
change over time.
World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0.) 
[44]—The WHODAS 2.0 [44] is a 12-item self-report measure that examines cognition, 
mobility, self-care, life activities, and participation in community activities. Responses are 
rated from 0 (none) to 4 (extreme) and then are summed to create a total score. Scores from 
the baseline visit were used to determine convergent and discriminant validity.
RAND-12 [45]—The RAND-12 [45] is a 12-item measure that is used to assess self-
reported mental and physical health. Physical and mental health composite scores (PHC and 
MHC) can be computed for the RAND-12 with scores ranging from 0 (low health) to 100 
(highest level of health). We examined baseline data to determine convergent and 
discriminant validity.
Clinician rated measures—Clinician rated measures of behavior, cognitive function, 
motor ability, and functioning were utilized to further examine convergent and discriminant 
validity of the HD-PRO-TRIAD™. The Problem Behaviors Assessment-short form (PBA-s) 
[46] was administered to examine the severity and frequency of eleven [11] behaviors. These 
behaviors included depression, suicide ideation, anxiety, irritability, aggression, apathy, 
perseverative thinking, obsessive compulsive behaviors, delusion, hallucinations, and 
disorientation. PBA-s severity scores range from 0 (symptom absent) to 4 (severe). 
Frequency scores range from 0 (never) to 4 (daily). For each behavior, the respective severity 
score is multiplied by the frequency score to create a final score for that behavior. Data was 
examined from the baseline visit for the purposes of the proposed analyses.
The Unified Huntington Disease Rating Scales (UHDRS) [46] is a standardized tool used in 
evaluating motor functioning, cognition, functioning, and independence. For cognitive 
measures we examined scores from the baseline visit on the color naming and word reading 
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versions of the Stroop [47] and the total score from the Symbol Digit Modalities Test [48], 
which both provide a measure of processing speed. The UHDRS Total Motor Scale (TMS) 
from the baseline visit was used to assess motor functioning. Scores on each item are rated 
from 0 (symptom absent) to 4 (severe symptom/could not complete); resulting in scores that 
range from 0 to 124, with higher scores indicating worse functioning. The final question on 
the TMS asks the clinician whether they can state with >99% certainty (based on a scale of 0 
[Normal] to 4 [>99% confidence]) that the participant has motor symptoms that are 
unequivocal signs of manifest HD. If the rater did not feel with at least 99% confidence that 
the participant had manifest HD (i.e., score of 4) then they were rated as prodromal. 
Baseline data was used to differentiate prodromal verses manifest status. Finally, the Total 
Functional Capacity (TFC) scale was administered at baseline to determine HD staging for 
manifest participants. Specifically, participants with scores from 7 to 13 on the TFC were 
classified as early-stage HD (stages I and II), and those with scores less than 7 were 
classified as late-stage HD (stages III, IV & V) [49].
Statistical analysis
Statistical analysis was performed using SAS 9.4 software [50]. Reliability measures of the 
Cron-bach’s α (minimal acceptable level ≥ 0.70) [51] were estimated for each of the HD-
PRO-TRIAD™domains. Floor and ceiling effects defined by the percent of participants who 
answered either 1 (floor) or 5 (ceiling) were calculated for each domain and the total score 
of the HD-PRO-TRIAD™ (minimal acceptable rates ≤ 20%) [52, 53]. Preliminary data 
analysis determined that distributions for each domain and the total HD-PRO-TRIAD™ did 
not meet normality assumptions and therefore non-parametric analyses were used as 
appropriate. Convergent and discriminant validity were examined between each of the three 
HD-PRO-TRIAD™ domains relative to the standardized clinician rated items and the 
already established patient reported outcome measures using Spearman-rho correlations. To 
support convergent validity, correlations between each HD-PRO-TRIAD™ domain and its 
associated comparator (e.g., motor domain with other measures of motor function) should be 
moderate to high (i.e., 0.60–0.80), but should not exceed 0.80 (which would be indicative of 
too much overlap). Correlations between each HD-PRO-TRIAD™ domain and the other 
comparator domains clinician-rated measures of function should be small to moderate (i.e., 
0.30–0.59) [54]. As the items from the HD-PROTRIAD™ were drawn from other existing 
measures, we excluded these measures from the reliability matrix used to evaluate 
convergent/discriminant validity (e.g., motor domain was not compared to HDQLIFE-
Chorea, cognitive domain was not compared to Neuro-QoL-Executive Function).
Known groups validity was assessed using a one-way ANOVA (Kruskal-Wallis Test method) 
to examine whether each domain including the total HD-PRO-TRIAD™ score could 
differentiate between prodromal, early, and late stage individuals. Prodromal participants 
should report better functioning than early stage participants, who should report better 
functioning than the late stage group. For domains with significant Kruskal-Wallis findings, 
Mann-Whitney U post-hoc tests were then conducted to determine where these differences 
were most prominent.
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Next, measurement error was calculated for each domain of the HD-PRO-TRIAD™. This 
was done by calculating the Standard Error of Measurement (SEM), which uses the formula: 
SEM = SD * 1 − Cronbach′s Alpha [55, 56]; baseline standard deviations and Cronbach’s 
alphas were used in this calculation. The SEM is an index of absolute reliability that can be 
used to create a confidence interval around an individual’s observed score that estimates the 
true score for that individual [57]. Furthermore, the Minimal Detectable Change (MDC) was 
calculated as: MDC = 1.96 * SEM * 2 [58]. The MDC is a measure of the minimal change 
between assessments that is not due to variation in measurement [57–59]. As suggested by 
Beckerman (2001), a 95% error band was calculated for change scores from baseline to 12-
month follow-up to detect the amount of change that is real/relevant [58]. For easier 
interpretability, SEMs and MDCs are presented in percentages (SEM or MDC divided by the 
mean of all observations across assessments, times one -hundred) [59].
Finally, to examine responsiveness to change over time, participants were categorized into 2 
groups using the EQ-5D Health Scale: those with significant health declines, and those with 
no changes or improvements. These classifications were made by subtracting the baseline 
EQ-5D Health Scale scores from either the 12-month or the 24-month scores, and then 
determining if the resulting change scores were ≥ 1SD below the mean for this sample 
(“health decline”) [60–62];sample means for the 12-month change scores were M = 0.36, 
SD = 15.54 and sample means for the 24-month change scores were M = 2.02, SD = 15.30. 
In order to be included in the 12-month “health decline” group, change scores must be 
≥15.54. Similarly, in order to be included in the 24-month “health decline” group, change 
scores must be ≥ 15.30. HD-PRO-TRIAD™ change scores for the group who reported 
health declines were compared to the group who reported no change/improvements using 
Mann-Whitney U tests. We hypothesized that participants who reported greater health 
declines on the EQ-5D would have higher HD-PRO-TRIAD™ change scores (towards 
worse functioning) than those who stayed the same/improved.
Standardized Response Means (SRM) were then calculated by dividing the average change 
from baseline to follow-up (12-month and 24-month) and dividing by the standard deviation 
of the change for each of the HD-PRO-TRIAD™ domains [63, 64]. Effect sizes between 
0.00 and |0.19 were considered “negligible,” |0.20| to |0.49| were “small,” |0.50| to |0.79| 
were “medium,” and |0.80| were “large” [63]. We hypothesized that participants who 
reported significant health declines would have SRM effect sizes < −0.20 and that those who 
reported staying the same/improving would have SRM effect sizes between −0.19 and 0.19 
(i.e., negligible change).
RESULTS
Demographic data
Four hundred and eighty-two individuals with either prodromal (n = 192) or manifest HD 
(early stage n = 193 or late stage n = 97) completed enough items from the HD-PRO-
TRIAD™ to enable the calculations of a total score. Groups did not differ on gender (χ22 = 
3.47, p = 0.17). Groups differed significantly in age (F[2, 479] = 43.97, p < 0.0001). The 
average age of the prodromal group (x = 42.5) was nine years younger than the early group 
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(xs = 52.0) and twelve years younger than the late stage group (x = 55.4). These age 
differences across groups were expected as HD is progressive [4]. The difference for race 
was also significant (χ26 = 30.59, p = 0.006); the late HD group had a larger proportion of 
African Americans than either of the other two staging groups. Group did not differ 
significantly in ethnicity (χ24 = 6.35, p = 0.17). Education was significantly different (F[2, 
463] = 15.85, p < 0.0001) among groups; the prodromal group had completed more years of 
education than either of the manifest groups. The late-stage group had significantly more 
CAG trinucleotide repeats than either of the other HD groups (F[2, 463] = 9.20; p = 0.0001). 
Full demographic information is provided in Table 1. A total of 118 participants (24.5%) 
completed all three study visits. Those who completed all three assessments did not differ on 
gender, race, ethnicity, or marital status. Not surprisingly, there were significantly fewer late-
stage participants to complete all three assessments (χ22 = 18.54, p = 0.0001).
Internal Consistency
The HD-PRO-TRIAD™ and all three of the symptom domains and the total score showed 
excellent overall internal consistency (all Cronbach’s α > 0.90;Table 2).
Floor and ceiling effects
In general, floor and ceiling effects were acceptable for the three HD-PRO-TRIAD™ 
domains (Table 2). The only exception was that the Motor domain exceeded the a priori 
cutoff (≤ 20%). Further examination indicated that the prodromal group was driving this 
floor effect (83% of the individuals exhibiting floor effects were in the prodromal group).
Convergent and discriminant validity
Table 3 highlights the Spearman-rho correlations among the HD-PRO-TRIAD™ domains 
and total score and comparator measures. In general, the pattern of the correlations 
supported convergent and discriminant validity. Specifically, the HD-PROTRIAD™ was 
moderately correlated (r≥ 0.45, with the exception of the RAND-12 MHC) with all 
clinician-rated measures and all PROMIS measures, and had the highest correlations with 
the general HRQOL measures. The Emotional/Behavioral Dyscontrol domain had the 
strongest relationships with other measures of mood, and less robust relationships with 
measures of cognition or motor functioning. Similar patterns were seen for the Motor 
domain. For the Cognitive domain, correlations were highest with the WHODAS and the 
Neuro-QoL measures of motor functioning, but were also strong between other measures of 
thinking and memory.
Known groups validity
Known groups validity was supported for the total score of the HD-PRO-TRIAD™ as well 
as each of the three domains (Table 4). Each of these domains was able to differentiate 
between the three HD groups. The exception to this was for the Emotional and Behavioral 
Dyscontrol domain, the measure was unable to differentiate between early and late-stage 
participants.
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Measurement error
All SEM% values were 11.19% or lower, indicating that the difference between observed 
scores and true scores is minimal (Table 5). The 95% MDC error band suggests that for each 
domain, less than a one-integer change in scores is sufficient in detecting real change. For 
the total HD-PRO-TRIAD™, less than a two-integer change in scores implies real change 
not due to variation in measurement.
Responsiveness to change over time
Table 6 highlights 12- and 24-month responsiveness data. From baseline to 12-months, 
scores for all HD-PRO-TRIAD™ domains (except emotional and behavioral dyscontrol) and 
the total score were worse for participants who had significant declines in health; these 
effect sizes were small (except for emotional and behavioral dyscontrol which was 
negligible). There were no significant differences in 12-month change scores between 
participants who reported worsened health and those who reported same/improved health. 
From baseline to 24-months, scores for all HD-PRO-TRIAD™ domains and the total score 
were worse for participants who had significant declines in health (again determined by 
EQ-5D Health Scale scores); all effect sizes were moderate. There were significant 24-
month differences between those with health declines and those with no changes/
improvements for all HD-PROTRIAD™ domains (except motor) and the total score.
DISCUSSION
The sensitive evaluation of PROs in HD has been limited by a lack of HD-specific measures 
of health-related quality of life. To address this need, the HD-PRO-TRIAD™ was developed 
to evaluate the triad of symptoms characteristic of HD (cognition, emotional/behavioral 
dyscontrol, and motor function). Findings support the clinical utility of the HD-PRO-
TRIAD™ as a valid measure of HRQOL in individuals with HD.
Findings replicate previous work on the HD-PROTRIAD™ as internal consistency was 
excellent and convergent/discriminant validity was supported. The exception to this was in 
regards to the discriminant validity of the Cognition domain, for which the highest 
correlations were with physical functioning measures. One possible explanation for this 
finding is that motor and cognitive declines occur at similar rates, or as an alternative, it is 
possible that individuals with HD have difficulty distinguishing motor difficulties form 
cognitive difficulties, as these two things are interrelated and can go hand in hand. On the 
other hand, the moderate relationships with the emotional functioning measures are 
consistent with previous findings on the HD-PRO-TRIAD™, and is not especially surprising 
given that self-reported cognition generally exhibits moderate relationships with measures of 
mood and objective measures of cognition, and sometimes reflects overall distress rather 
than objective cognitive dysfunction [65–72]. Taken together, findings were generally 
consistent with our proposed hypotheses and suggest that the HD-PROTRIADTM is a valid 
measure of HRQOL for people with HD.
The current study also expands upon previous literature by examining floor effects, known 
groups validity, and responsiveness of the HD-PRO-TRIAD™. The total score for the HD-
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PRO-TRIADTM was free of both ceiling and floor effects. Furthermore, the domain scores 
were also free of floor and ceiling effects (with the exception of the Motor domain, which 
had some evidence for a floor effect secondary to a lack of motor manifestation in prodromal 
HD participants). Such findings are consistent with other measures of HRQOL in HD. 
Specifically, measures that are comprised of multiple HRQOL domains, typically do not 
exhibit floor or ceiling effects, but when the focus is on a single domain, there are often floor 
effects for prodromal participants (which is not surprising given that these measures are 
typically designed to evaluate dysfunction, and these individuals are not yet exhibiting 
problems in these areas) [73, 74].
In addition, known groups validity for the HD-PRO-TRIAD™ scores was also supported. 
Specifically, individuals with late-HD reported worse functioning than those with early- or 
prodromal HD, and individuals with early-HD reported worse functioning that individuals 
with prodromal HD across nearly all domain and the total scale of the HDPRO-TRIADTM. 
The only exception was a lack of difference between early-and late-HD for the Emotional 
and Behavioral Dyscontrol domain. These findings generally provide empirical support for 
the construct validity of HD-PRO-TRIAD™.
Additionally, measurement error and minimal detectable change scores were small, and 
generally were less than a 1-point difference for each domain and less than 2-points for the 
HD-PRO-TRIAD™ total score. Therefore, clinicians and researchers can be confident that a 
participant’s score will reflect their true score, and that change scores larger than those in 
Table 4 reflect real change rather than error in measurement.
Finally, the HD-PRO-TRIAD™ was also found to have acceptable responsiveness to self-
reported change over time. There were small 12-month effect sizes for all HD-PRO-
TRIAD™ domains (except emotional and behavioral dyscontrol), and moderate 24-month 
effect sizes for all domains and the total score. The fact that effect sizes were evident and 
based solely on change over time (i.e., expected declines from disease progression) and not 
on changes due to clinical interventions, makes this finding especially promising. In 
addition, while there were not significant differences between the group with significant 
health declines and those with no change/improvements at 12-months, there were significant 
group differences in change at 24-months which provides additional support for 
responsiveness. Specifically, while the absence of significant group differences at 12-months 
may raise concerns regarding the sensitivity of the measure, previous research indicates that 
non-significant group differences do not necessarily indicate a trivial finding [75–78]. 
Furthermore, the significant group differences at 24-months (despite the small sample size) 
mitigates these concerns. Thus, findings support responsiveness to change; findings that we 
anticipate will be more robust given a larger sample size and/or the introduction of an 
effective clinical intervention.
While this study provides important reliability and validity data for the HD-PRO-TRIAD™, 
we also recognize several limitations. First, as described above, we did not administer all of 
the items of the HD-PROTRIAD™ and therefore, findings using the full form, as intended, 
may not be fully comparable. Additionally, test-retest reliability was not examined in this 
study and further work is needed to provide this information. Also, as the measurement error 
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and minimal detectable change was calculated from just one aspect of the reliability 
coefficient (the Cronbach’s alpha), there may be minor variation in these findings should this 
study be replicated. Furthermore, the retention rates for the 24-month sample size were not 
ideal and dropout rates, especially for those with more severe HD may have influenced 
reported longitudinal findings. Finally, given that this sample was primarily female and 
Caucasian, generalizability to other groups (i.e., men, as well as racial and ethnic minorities 
with HD) may be less robust.
Despite these limitations, this study provides additional support for the reliability and 
validity of HD-PRO-TRIAD™. Findings supporting internal consistency and convergent and 
discriminant validity replicated previous published work. New analyses from this study, 
demonstrating the lack floor and ceiling effects, as well as analyses supporting known-
groups validity, minimal measurement error, and responsiveness of the HD-PRO-TRIAD™, 
provide additional support for the clinical utility of this measure. Ultimately, findings 
suggest that the HD PRO-TRIAD™ is a reliable and valid assessment tool for evaluating 
HRQOL individuals with prodromal and manifest HD.
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Appendix A.: Questions from original HD-PRO-TRIAD™ paper administered 
for the purposed of this study.
HD-PRO-TRIADTM Domains
Cognitive: Rated from 1 (Very often; Cannot Do) to 5 (Never; None)
• • In the past 7 days…I had trouble keeping track of what I was doing if I was 
interrupted
• • In the past 7 days…I had trouble concentrating
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• • In the past 7 days…I had difficulty doing more than one things at a time
• • In the past 7 days…I had trouble planning out steps of a task
• • In the past 7 days…I had trouble remembering new information, like phone 
numbers or simple instructions
• • How much difficulty do you currently have… getting things organized?
• • How much difficulty do you currently have… keeping important personal 
papers such as bills, insurance documents and tax?
• • How much difficulty do you currently have… learning new tasks or 
instructions?
• • How much difficulty do you currently have… remembering a list of 4 or 5 
errands without writing it down?
Emotional/Behavioral Dysfuntion: Rated from 1 (Never) to 5 (Always)
• • In the past 7 days…It was hard to control my behavior
• • In the past 7 days…I was irritable around other people
• • In the past 7 days…I was bothered by little things
• • In the past 7 days…I became easily upset
• • In the past 7 days…I said or did things without thinking
• • In the past 7 days…I got impatient with other people
• • In the past 7 days…I felt impulsive
• • In the past 7 days…It was hard to adjust to unexpected changes
• • In the past 7 days…I was in conflict with others
• • In the past 7 days…I said or did things that other people probably thought were 
inappropriate
• • In the past 7 days…I threatened violence toward people or property
• • In the past 7 days…I felt angry
• • In the past 7 days… I had trouble controlling my temper
Motor Function: Rated from 1 (Never) to 5 (Always)
• • In the past 7 days…How often did you feel unsteady when you were standing?
• • In the past 7 days…How often did you have movements (e.g., chorea)?
• • In the past 7 days…How often were you unable to stay still?
• • In the past 7 days…How often did your movements (e.g., chorea) impact your 
ability to hold things, like a glass or for
Boileau et al. Page 13
J Huntingtons Dis. Author manuscript; available in PMC 2018 August 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
• • In the past 7 days…How often did you experience severe movements (e.g., 
chorea)?
• • How much difficulty do you currently have...speaking clearly?
• • In the past 7 days…How often did you have to speak slowly for other people to 
understand you?
• • In the past 7 days…How often did choking interfere with your ability to eat?
• • In the past 7 days…How often were you bothered by your choking?
• • In the past 7 days…How often were you unable to maintain a conversation?
• • In the past 7 days…How often were you unable to swallow?
• • In the past 7 days…How often did you have shakiness?
• • In the past 7 days…I needed help doing my usual activities.
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Table 1
Demographic Characteristics of Individuals with HD, stratified by stage of the disease
Variable Prodromal-HD (N = 192) Early-HD (N = 193) Late-HD (N = 97) Combined Sample (N = 482)
Age (Years)
 M(SD) 43.00(12.10) 52.10(12.20) 55.40(11.70) 49.14 (13.12)
Gender (%)
 Female 63.50 54.40 56.70 58.50
 Male 36.50 45.60 43.30 41.50
Race (%)
 White 97.40 97.40 92.80 96.10
 African American 0.00 1.00 7.20 1.30
 Other 2.10 1.60 0.00 1.40
 Unknown 0.50 0.00 0.00 0.20
Ethnicity (%)
 Not Hispanic or Latino 92.20 93.30 93.60
 Hispanic or Latino 1.60 3.10 2.10 4.10
 Not Provided 6.20 3.60 1.00 2.30
Education (# of years)
 M (SD) 15.97 (2.81) 14.73 (2.78) 14.21 (2.51) 15.12(2.83)
Marital Status (%)
 Single, Never Married 16.10 14.60 11.30 14.60
 Married 66.70 55.70 62.90 61.50
 Separated/Divorced 14.10 22.40 22.70 19.10
 Widowed 0.00 3.10 3.10 1.90
 Living with Partner 3.10 4.20 0.00 2.90
CAG Repeats
 M (SD) 42.18 (2.93) 42.93 (3.54) 44.72 (7.32) 42.78 (4.04)
Note. HD = Huntington disease.
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Table 2
Descriptive data for HD-PRO-TRIAD™
HD-PRO-TRIAD™ Domain N # of Items Cronbach’s α % of Sample with Floor 
Effects
% of sample 
with Ceiling 
Effects
Median (IQR)
BASELINE VISIT
Cognition 482 9 0.94 9.96 0.41 2.38 (1.83)
Emotional and Behavioral Dyscontrol 482 13 0.94 12.24 0.00 1.62(1.08)
Motor 482 13 0.95 24.48 0.21 1.62 (1.38)
Total Score 482 35 0.96 2.07 0.00 5.64 (3.46)
12-MONTH VISIT
Cognition 304 9 0.93 9.87 0.33 2.25 (1.81)
Emotional and Behavioral Dyscontrol 304 13 0.95 15.46 0.00 1.54 (1.08)
Motor 304 13 0.96 23.03 0.00 1.52(1.32)
Total Score 304 35 0.96 3.95 0.00 5.75 (3.61)
24-MONTH VISIT
Cognition 118 9 0.96 10.17 0.00 2.31 (1.88)
Emotional and Behavioral Dyscontrol 118 13 0.95 14.41 0.00 1.54 (1.08)
Motor 118 13 0.95 23.73 0.00 1.38 (1.08)
Total Score 118 35 0.97 2.54 0.00 5.25 (3.99)
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Table 4
Known groups validity for the HD-PRO-TRIAD™
HD-PRO-TRIAD™ Domain Prodromal HD (n = 192)
Median (Q1*,Q3*)
Early-HD (n = 193)
Median (Q1*,Q3*)
Late-HD (n = 97)
Median (Q1*,Q3*)
χ2 p-value
Cognitiona,b,c 1.63 (1.13, 2.38) 2.50(1.88,3.38) 3.50 (2.63, 4.25) 120.66 <0.0001
Emotional and Behavioral Dyscontrola,b 1.46(1.15, 1.92) 1.69 (1.23, 2.46) 1.85 (1.23, 2.54) 10.00 0.0007
Motora,b,c 1.00(1.00, 1.17) 2.00(1.31,2.62) 2.80 (2.00, 3.46) 222.32 <0.0001
Totala,b,c 4.17 (3.52, 5.55) 6.26 (5.03, 7.69) 8.36 (6.78, 9.42) 145.97 <0.0001
*Q1: Quantile 1; Q3: Quantile 3. 50% of data falls between this range.
a
Indicates significant differences between prodromal and early –HD.
b
Indicates significant differences between prodromal and late-HD.
c
Indicates significant differences between early-HD and late-HD.
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Table 5
Measurement Error: Standard Error of Measurement (SEM) and Minimal Detectable Change (MDC)
HD-PRO-TRIAD Domain d (95% CI)* SEM SEM % 95% MDC** MDC %
Cognition −0.02 (−1.29, 1.26) 0.27 10.92 −0.76–0.72 30.27
Emotional and Behavioral Dyscontrol −0.02 (−1.23, 1.19) 0.18 10.04 −0.52–0.48 27.83
Motor −0.04 (−1.03, 0.95) 0.21 11.19 −0.61–0.53 31.01
Total Score −0.08 (−2.56, 2.40) 0.46 7.62 −1.36–1.20 21.12
Note: SEM = Standard error of measurement; MDC = Minimal Detectable Change; CI = Confidence Interval.
*d: Average change score. From Baseline to 12-month.
**95% MDC reflects error band around the change from baseline to 12-month visits.
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Table 6
Standardized Response Means for responsiveness (self-report change between assessments)
HD-PRO-TRIAD™ Domain Baseline to 12 Months Baseline to 24 Months
Sample Size Significant 
Health 
Decline (n 
= 42)
Same/
Improved 
(n = 254)
P-value* Sample Size Significant 
health 
Decline (n 
=14)
Same/
Improved 
(n = 104)
P-value*
Cognitive 296 −0.22 0.00 0.18 118 −0.72 −0.06 0.03
Emotional/Behavioral Dyscontrol 296 0.03 −0.04 0.93 118 −0.62 0.04 0.01
Motor 296 −0.27 −0.04 0.32 118 −0.65 −0.16 0.10
Total 296 −0.21 −0.03 0.40 118 −0.75 −0.06 0.01
*P-value based on results of the Mann-Whitney U test comparing change scores between the 2 groups; bolding for p-values indicates significant 
group differences (i.e., p < 0.05).
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